ES2184310T3 - Formulacion autoemulsionante para compuestos lipofilos acidos. - Google Patents

Formulacion autoemulsionante para compuestos lipofilos acidos.

Info

Publication number
ES2184310T3
ES2184310T3 ES98936888T ES98936888T ES2184310T3 ES 2184310 T3 ES2184310 T3 ES 2184310T3 ES 98936888 T ES98936888 T ES 98936888T ES 98936888 T ES98936888 T ES 98936888T ES 2184310 T3 ES2184310 T3 ES 2184310T3
Authority
ES
Spain
Prior art keywords
self
pharmaceutically acceptable
formulation
lipofil
emulsioning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98936888T
Other languages
English (en)
Inventor
Walter Morozowich
Ping Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2184310T3 publication Critical patent/ES2184310T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a una nueva composición farmacéutica basada en la utilización de una cierta cantidad de una amina básica, conteniendo esta composición un compuesto de piranona como agente farmacéuticamente activo; una cantidad de amina básica que varía aproximadamente entre 0,1 y 10% en peso de la composición total, uno o varios solventes farmacéuticamente aceptables; y uno o varios tensioactivos farmacéuticamente aceptables. Esta composición, que puede contener además uno o varios aceites farmacéuticamente aceptables; se presenta en forma de una formulación autoemulsionante que presenta una concentración elevada de compuestos de piranona lipofílicas y una biodisponibilidad oral importante para estos últimos.
ES98936888T 1997-07-29 1998-07-27 Formulacion autoemulsionante para compuestos lipofilos acidos. Expired - Lifetime ES2184310T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5401297P 1997-07-29 1997-07-29

Publications (1)

Publication Number Publication Date
ES2184310T3 true ES2184310T3 (es) 2003-04-01

Family

ID=21988155

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98936888T Expired - Lifetime ES2184310T3 (es) 1997-07-29 1998-07-27 Formulacion autoemulsionante para compuestos lipofilos acidos.

Country Status (24)

Country Link
US (1) US6231887B1 (es)
EP (1) EP0989851B1 (es)
JP (1) JP4524367B2 (es)
KR (1) KR100509131B1 (es)
CN (1) CN1112927C (es)
AT (1) ATE225174T1 (es)
AU (1) AU728626B2 (es)
BR (1) BR9810729B1 (es)
CA (1) CA2294033C (es)
CY (1) CY2006002I2 (es)
CZ (1) CZ296957B6 (es)
DE (1) DE69808463T2 (es)
DK (1) DK0989851T3 (es)
ES (1) ES2184310T3 (es)
FI (1) FI20000172A7 (es)
HU (1) HU228923B1 (es)
NO (1) NO323425B1 (es)
NZ (1) NZ502566A (es)
PL (1) PL192865B1 (es)
PT (1) PT989851E (es)
RU (1) RU2202346C2 (es)
SI (1) SI0989851T1 (es)
SK (1) SK284616B6 (es)
WO (1) WO1999006044A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
DE60017720T2 (de) * 1999-03-31 2006-01-12 Pharmacia & Upjohn Co., Kalamazoo Pharmazeutische emulsionen für retroviral-protease hemmende verbindungen
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
NZ526169A (en) * 2000-10-31 2005-12-23 Boehringer Ingelheim Pharma Oral dosage self-emulsifying formulations of pyranone protease inhibitors
SE0102993D0 (sv) * 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
MXPA05010338A (es) * 2003-04-02 2005-11-17 Boehringer Ingelheim Int Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c.
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
EP1672985A1 (en) * 2003-10-07 2006-06-28 Eli Lilly And Company Liquid formulations of ractopamine
EP1814549A2 (en) * 2004-11-19 2007-08-08 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
CA2583195A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and reverset
EP1819348A1 (en) * 2004-12-01 2007-08-22 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
JP5028885B2 (ja) * 2006-07-04 2012-09-19 大正製薬株式会社 ユビデカレノン含有自己乳化組成物
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
JP5607736B2 (ja) * 2009-07-07 2014-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスプロテアーゼ阻害剤のための医薬組成物
EP2488022B1 (en) 2009-10-16 2018-01-10 Mochida Pharmaceutical Co., Ltd. Compositions
RU2419426C1 (ru) * 2010-04-26 2011-05-27 Всеволод Иванович Киселев Лекарственное средство на основе дииндолилметана (dim) с повышенной биодоступностью и его использование в лечении гиперпластических и воспалительных заболеваний человека
EA027666B1 (ru) 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
AU2014204739B2 (en) * 2013-01-14 2016-08-11 Infirst Healthcare Limited Compositions and methods for treating severe pain
KR20170120161A (ko) * 2015-03-05 2017-10-30 알러간, 인코포레이티드 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
DE3300793A1 (de) * 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Coccidiosemittel
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
US5376688A (en) 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
EP0769936A1 (en) * 1994-07-22 1997-05-02 G.D. Searle & Co. Self-emulsifying drug delivery system
JPH11504028A (ja) * 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム 油／水エマルジョンを作り出す自己乳化性配合物
EA001413B1 (ru) 1995-06-06 2001-02-26 Ф. Хоффманн-Ля Рош Аг Фармацевтическая композиция, содержащая ингибитор протеиназы и моноглицерид
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
ATE225174T1 (de) 2002-10-15
HUP0002440A3 (en) 2001-10-29
PT989851E (pt) 2002-12-31
CA2294033A1 (en) 1999-02-11
NO20000466D0 (no) 2000-01-28
DE69808463D1 (de) 2002-11-07
FI20000172L (fi) 2000-01-28
CN1112927C (zh) 2003-07-02
PL338335A1 (en) 2000-10-23
KR100509131B1 (ko) 2005-08-18
RU2202346C2 (ru) 2003-04-20
NZ502566A (en) 2002-03-28
CZ296957B6 (cs) 2006-08-16
FI20000172A7 (fi) 2000-01-28
AU728626B2 (en) 2001-01-11
EP0989851A1 (en) 2000-04-05
KR20010022369A (ko) 2001-03-15
WO1999006044A1 (en) 1999-02-11
PL192865B1 (pl) 2006-12-29
JP2002510330A (ja) 2002-04-02
SI0989851T1 (en) 2003-04-30
SK162000A3 (en) 2000-12-11
NO323425B1 (no) 2007-04-30
BR9810729B1 (pt) 2010-07-13
CZ2000156A3 (cs) 2000-05-17
CA2294033C (en) 2007-01-09
BR9810729A (pt) 2000-08-08
CN1261796A (zh) 2000-08-02
DE69808463T2 (de) 2003-06-26
JP4524367B2 (ja) 2010-08-18
NO20000466L (no) 2000-03-28
EP0989851B1 (en) 2002-10-02
CY2006002I1 (el) 2011-02-02
US6231887B1 (en) 2001-05-15
DK0989851T3 (da) 2003-01-27
CY2006002I2 (el) 2012-01-25
AU8573898A (en) 1999-02-22
SK284616B6 (sk) 2005-07-01
HK1028879A1 (en) 2001-03-09
HUP0002440A2 (hu) 2001-09-28
HU228923B1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
ES2184310T3 (es) Formulacion autoemulsionante para compuestos lipofilos acidos.
UY27320A1 (es) Nuevas composiciones farmacéuticas
TW200531696A (en) Pharmaceutical formulations of bisphosphonates
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
ATE554746T1 (de) Pharmazeutische zusammensetzungen mit cyclosporin
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
AR019690A1 (es) Formulacion farmaceutica para aerosoles con dos o mas sustancias activas
IL179718A0 (en) Pharmaceutical composition containing irbesartan
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
UY29905A1 (es) Formulación farmacéutica de absorción oral y su método de administración
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
AR032360A1 (es) Compuesto derivado de acido homoiminopiperidinil hexanoico, composicion farmaceutica que lo comprende y compuestos intermediarios que se usan en su preparacion
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
BR9916830A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos e budesonide
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
ECSP088732A (es) Aerosoles dosificadores para la administración de preparaciones farmacéuticas
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
BR0316724A (pt) Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
DK0853476T5 (da) Nimesulidholdigt farmaceutisk præparat til topisk anvendelse
DE60017720D1 (de) Pharmazeutische emulsionen für retroviral-protease hemmende verbindungen
PE20011092A1 (es) Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene reducida irritacion de la piel
BRPI0519248A2 (pt) formulaÇço oral de liberaÇço imediata de um composto ativo, e, mÉtodo para a preparaÇço de uma formulaÇço